Gemfibrozil-induced myositis in a patient with normal renal function

Annals of Pharmacotherapy

Volumn 44, Issue 1, 2010, Pages 211-214

  Hahn, Martin ^a   Sriharan, Kalavally ^b   McFarland, M Shawn ^b,c  

^a BIRMINGHAM VA MEDICAL CENTER   (United States)

^b Primary Care   (United States)

^c University of Tennessee   (United States)

Author keywords

Gemfibrozil; Myositis

Indexed keywords

ALANINE AMINOTRANSFERASE; AMFEBUTAMONE; ASPARTATE AMINOTRANSFERASE; CREATINE KINASE; CREATININE; GEMFIBROZIL; GLIMEPIRIDE; INSULIN ASPART; INSULIN GLARGINE; LISINOPRIL; OMEPRAZOLE; PARACETAMOL; PREGABALIN; SILDENAFIL; TRAVOPROST;

AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTHRITIS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BEDTIME DOSAGE; CASE REPORT; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DRUG WITHDRAWAL; EVENING DOSAGE; GASTROESOPHAGEAL REFLUX; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; IMPOTENCE; KIDNEY FUNCTION; MALE; MYOSITIS; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE HYPERTROPHY;

AGED; ANTILIPEMIC AGENTS; GEMFIBROZIL; HUMANS; KIDNEY; KIDNEY FUNCTION TESTS; MALE; MYOSITIS;

EID: 74549179014     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1M411     Document Type: Article

References (29)

1. Schoonjans K, Staels B, Auwerx J. Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. J Lipid Res 1996;37:907-25.
2. Fruchart JC, Brewer HB Jr, Leitersdorf E. Consensus for the use of fibrates in the treatment of dyslipoproteinemia and coronary heart disease. Am J Cardiol 1998;81:912-7.
3. Leaf DA, Connor WE, Illingworth DR, Bacon SP, Sexton G. The hypolipidemic effects of gemfibrozil in type V hyperlipidemia: a doubleblind, crossover study. JAMA 1989;262:3154-60.
4. Blane GF. Comparative toxicity and safety profile of fenofibrate and other fibric acid derivatives. Am J Med 1987;83(suppl 5B):26-36.
5. Palmer RH. Effects of fibric acid derivatives on biliary lipid composition. Am J Med 1987;83(suppl 5B):37-43.
6. Remick J, Weintraub H, Setton R, Offenbacher J, Fisher E, Schwartzbard A. Fibrate therapy: an update. Cardiol Rev 2008;26:129-39.
7. Package insert. Lopid (gemfibrozil). New York, NY: Pfizer, Inc., November 2008.
8. Package insert. Gemfibrozil. Hauppauge, NY: InvaGen Pharmaceuticals, Inc., September 2007.
9. Tobert JA. Efficacy and long-term adverse effect pattern of lovastatin. Am J Cardiol 1988;62(suppl):28J-34J.
10. Tal A, Rajeshaware M, Isley W. Rhabdomyolysis associated with simvastatin-gemfibrozil therapy. South Med J 1997;90:546-7.
11. Murdock DK, Murdock AK, Murdock RW, et al. Long-term safety and efficacy of combination gemfibrozil and HMG-CoA reductase inhibitors for the treatment of mixed lipid disorders. Am Heart J 1999; 138:151-5.
12. Alsheikh-Ali AA, Kuvin JT, Karas RH. Risk of adverse events with fibrates. Am J Cardiol 2004;94:935-8.
13. Rosen RS. Current overview of statin-induced myopathy. Am J Med 2004;116:408-16.
14. McClure DL, Valuck RJ, Glanz M, Murphy JR, Hokanson JE. Statin and statin-fibrate use was significantly associated with increased myositis risk in a managed care population. J Clin Epidemiol 2007;60:812-8.
15. Package insert. Zocor (simvastatin). Whitehouse Station, NJ: Merck and Co., Inc., June 2008.
16. Package insert. Mevacor (lovastatin). Whitehouse Station, NJ: Merck and Co., Inc., September 2008.
17. Package insert. Crestor (rosuvastatin calcium). Wilmington, DE: AstraZeneca Pharmaceuticals LP, February 2009.
18. McKenney JM. Dyslipidemias, atherosclerosis, and coronary heart disease. In: Koda-Kimble MA, ed. Applied therapeutics: the clinical use of drugs. 8th ed. Baltimore: Lippencott Williams & Wilkins, 2005:13-28-13-37.
19. Warren JD, Blumbergs PC, Thompson PD. Rhabdomyolysis: a review. Muscle Nerve 2002;25:332-47.
20. Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: primary-prevention trials with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987;317:1237-45.
21. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 1999;341:410-8.
22. Gaist D, Garcia-Rodriquez LA, Huerta C, et al. Lipid-lowering drugs and risk of myopathy: a population-based follow-up study. Epidemiology 2001;12:565-9.
23. Chow T, Chow W. Acute compartment syndrome: an unusual presentation of gemfibrozil induced myositis. Med J Aust 1993;158:48-9.
24. Magarian GJ, Lucas LM, Colley C. Gemfibrozil-induced myopathy. Arch Intern Med 1991;151:1873- 4.
25. American Academy of Orthopaedic Surgeons. http://orthoinfo.aaos.org/ topic.cfmtopic = a00198#Diagnosis (accessed 2009 Jun 1).
26. Drake LA, Dinehart SM, Farmer ER, et al. Guidelines of care for dermatomyositis. J Am Acad Dermatol 1996;34:824-9.
27. Amato AA, Griggs RC. Treatment of idiopathic inflammatory myopathies. Curr Opin Neurol 2003;16:569-75.
28. Hicks JE, Miller F, Plotz P, et al. Isometric exercise increases strength and does not produce sustained creatinine phosphokinase increases in a patient with polymyositis. J Rheumatol 1993;20:1399-401.
29. Naranjo CA, Busto U, Sellers EM, et al. A method of estimating the probability of adverse drug interactions. Clin Pharmacol Ther 1981;30:239-45.